Publication:
Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix

dc.contributor.authorTangjitgamol S.
dc.contributor.authorManusirivithaya S.
dc.contributor.authorChoomchuay N.
dc.contributor.authorLeelahakorn S.
dc.contributor.authorThawaramara T.
dc.contributor.authorPataradool K.
dc.contributor.authorSuekwatana P.
dc.date.accessioned2021-04-05T04:32:12Z
dc.date.available2021-04-05T04:32:12Z
dc.date.issued2007
dc.date.issuedBE2550
dc.description.abstractThe prognosis of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is generally poor despite multimodality of treatments. We report a case of advanced stage cervical LCNEC that showed definite response to paclitaxel/carboplatin, resulting in years of survival. The patient was referred to our institution after undergoing a simple hysterectomy with bilateral salpingo-oophorectomy in her local hospital because of a ruptured metastatic ovarian mass. She declined pelvic radiation treatment, so adjuvant chemotherapy (six cycles of paclitaxel/carboplatin) was given for the residual pelvic nodal diseases. Clinical complete remission was obtained, with a disease-free period of 19 months. Systemic recurrent diseases also showed partial response to the same drug regimen for months with only minimal toxicity. However, she subsequently had progressive diseases in the liver and brain and finally died at 44 months after primary diagnosis and 19 months after recurrent diseases. © 2007 The Authors.
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of Obstetrics and Gynaecology Research. Vol 33, No.2 (2007), p.218-224
dc.identifier.doi10.1111/j.1447-0756.2007.00509.x
dc.identifier.issn13418076
dc.identifier.other2-s2.0-33847713390
dc.identifier.urihttps://hdl.handle.net/20.500.14740/4721
dc.rights.holderScopus
dc.subject.otherCarboplatin
dc.subject.otherCisplatin
dc.subject.otherEtoposide
dc.subject.otherPaclitaxel
dc.subject.otherAdrenal metastasis
dc.subject.otherAdult
dc.subject.otherArticle
dc.subject.otherAspiration biopsy
dc.subject.otherBrain metastasis
dc.subject.otherCancer chemotherapy
dc.subject.otherCancer regression
dc.subject.otherCancer staging
dc.subject.otherCancer survival
dc.subject.otherCase report
dc.subject.otherClinical feature
dc.subject.otherComputer assisted tomography
dc.subject.otherDisease free interval
dc.subject.otherDrug response
dc.subject.otherDrug substitution
dc.subject.otherFemale
dc.subject.otherHistopathology
dc.subject.otherHuman
dc.subject.otherHuman tissue
dc.subject.otherHysterectomy
dc.subject.otherLaboratory test
dc.subject.otherLarge cell carcinoma
dc.subject.otherLiver metastasis
dc.subject.otherLymph node metastasis
dc.subject.otherMultiple cycle treatment
dc.subject.otherNeuroendocrine tumor
dc.subject.otherOvary tumor
dc.subject.otherRecurrent disease
dc.subject.otherSalpingooophorectomy
dc.subject.otherUnspecified side effect
dc.subject.otherUterine cervix carcinoma
dc.subject.otherAdult
dc.subject.otherAntineoplastic Agents
dc.subject.otherAntineoplastic Agents, Phytogenic
dc.subject.otherBrain Neoplasms
dc.subject.otherCarboplatin
dc.subject.otherCarcinoma, Large Cell
dc.subject.otherCarcinoma, Neuroendocrine
dc.subject.otherChemotherapy, Adjuvant
dc.subject.otherCombined Modality Therapy
dc.subject.otherDisease Progression
dc.subject.otherFatal Outcome
dc.subject.otherFemale
dc.subject.otherHumans
dc.subject.otherLiver Neoplasms
dc.subject.otherNeoplasm Recurrence, Local
dc.subject.otherOvariectomy
dc.subject.otherPaclitaxel
dc.subject.otherUterine Cervical Neoplasms
dc.titlePaclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-33847713390&doi=10.1111%2fj.1447-0756.2007.00509.x&partnerID=40&md5=f5ff88a7c610ad00771b079509002ba5

Files